Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, other solid tumors

A novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers and one long considered "undruggable"—shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online.